An interventional study of Next Generation Extended Wear Sensors in Type 1 Diabetes and Type 2 Diabetes, sponsored by Medtronic MiniMed, Inc.. Recruiting at 19 sites in United States. Open to participants aged 2 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Medtronic MiniMed, Inc. (part of Medtronic) · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Diabetes Mellitus, Type 1 by Medtronic — 3 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Medtronic.
Among the 59 studies in Diabetes Mellitus, Type 1 by Medtronic, this one has the largest planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2026, is one of 49 with no phase, and was the 59th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →3 of the 59 studies in Diabetes Mellitus, Type 1 by Medtronic are open now, in 7 countries. Recruiting first, the newest first:
Medtronic MiniMed, Inc. · Sites in France, Netherlands
Ages 18+
Medtronic MiniMed, Inc. · Sites in France, Germany, Italy and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 2 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 1,500 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 103 across the 54 interventional studies, 274 across the 5 observational. Of the 49 that completed or were terminated, 42 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic MiniMed, Inc., one of the names counted as Medtronic. Under that name alone:
Medtronic MiniMed, Inc. is the lead sponsor of 13 studies on the registry; 4 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
2 of the studies in Diabetes Mellitus, Type 1 by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07228117Medtronic MiniMed, Inc.GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | 2027-01 |
| NCT06739811Medtronic MiniMed, Inc.Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes (CIP347) | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Diabetes Mellitus, Type 1 by Medtronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will collect sensor data in subjects with T1D or T2D, 2-80 years of age.
The study is a multi-center, prospective single-arm design without controls for adult and pediatric subjects with T1D or T2D. The study is anticipated to last approximately 24 months from first investigational center initiation to study completion (last subject, last visit completed). The subject's participation from study enrollment to study exit is approximately up to 46 days (including replacement sensor wear and repeat office procedures if needed).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has a clinical diagnosis of diabetes as stipulated according to the following age group:
If participating in glycemic challenges, has met the following conditions:
Exclusion Criteria:
Currently pregnant or planning to become pregnant during the time period of study participation
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will wear the sensor. Each subject and subject's parent/guardian/caregiver (if applicable) may insert and tape (if applicable) the study glucose sensors once trained or have them inserted and taped (if applicable) by the trained investigational center staff.
Device: Next Generation Extended Wear Sensors
Disposable Sensor (MMT-5600XNG and MMT-5600X) - labeled as DS5K and referred to as Unity
Primary Safety Endpoints
Descriptive summary will be used to characterize: * Skin assessment of subject's glucose sensor insertion sites * Adverse events (AE) to include: * Serious Adverse Events (SAE) * Device Related AEs * Procedure Related AEs * Serious Adverse Device Effects (SADE) * Unanticipated Adverse Device Effects (UADE) * Severe hypoglycemia * Diabetic Ketoacidosis (DKA) * Hyperosmolar Hyperglycemic State (HHS)
Time frame: Approximately up to 46 days
Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.
Of 105 industry-sponsored interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 14 months is above that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.